What Азафен Treats: Main Uses and Benefits

Azafen (Pipofezine) is generally used to address conditions within the affective disorder spectrum, where it is applied in symptomatic management. These medications are commonly used to help with illnesses like depression, which cause symptoms such as persistent sadness, fatigue, and changes in sleep or mood. The medication is considered relevant for easing symptoms in cases of neurotic depression, generalized depressive disorders of mild to moderate severity, and astheno-depressive disorders.

The medication is applied for mood stabilization, which contributes to symptomatic relief from persistent low mood, emotional flatness, and feelings of sadness. Furthermore, Azafen is used in situations where depressive states may be accompanied by significant symptoms of comorbid anxiety and emotional agitation, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Emotional Distress The medication assists with maintaining a sense of stability when symptoms are more noticeable, supporting patients during difficult episodes by easing distress associated with low mood, inner tension, and pervasive fatigue.

Regulatory References

1. NIH MedlinePlus overview of Antidepressants

Who can and cannot use Азафен?

Eligibility to use Азафен (Pipofezine) is strictly governed by a set of official contraindications established in regulatory documents. Use is prohibited for individuals presenting with specific pre-existing conditions or physiological states. This medicine is intended for use in the adult population only.

---

Contraindicated Populations

The following groups must not use this medication, as its use is formally contraindicated:

• Age: The pediatric population (children) is strictly excluded from treatment.
• Reproductive Status: Use is prohibited during pregnancy and the period of lactation (breastfeeding).
• Organ Function: Individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment.
• Cardiovascular/Cerebrovascular History: Patients with a history of acute ischemic heart disease, a recent myocardial infarction (heart attack), or those in a post-stroke state.
• Concomitant Therapy: Patients who are currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have a known hypersensitivity to the drug's components.

---

Eligibility Summary

Official labeling defines eligibility by exclusion; use is permitted only for adult patients who do not possess any of the documented contraindicating clinical or physiological conditions, nor are they receiving MAOIs. These contraindications represent mandatory and non-negotiable restrictions to minimize documented risks associated with use.

Interactions with other medicines and products

Official regulatory information for Азафен (Pipofezine) establishes specific restrictions based on its chemical class as a serotonergic agent.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a contraindicated combination due to the high risk of a severe pharmacodynamic interaction resulting in Serotonin Syndrome. A mandatory washout period is officially required between discontinuing MAOIs and initiating treatment with Азафен, and vice versa.

Pharmacodynamic and Substance Interactions

Co-administration with other Serotonergic Agents is restricted because of additive effects that reinforce serotonergic load. Combining with Central Nervous System (CNS) Depressants, including alcohol, is officially restricted because the pharmacodynamic interaction results in potentiation of sedation and impaired coordination. Similarly, co-use with anticholinergic medications is cautioned against due to the additive risk of anticholinergic symptoms.

Pharmacokinetic Interactions

The drug's metabolism is subject to pharmacokinetic interaction through the Cytochrome P450 enzyme system, specifically CYP2D6. Medicines that are CYP2D6 inhibitors may increase the plasma concentration of Азафен due to reduced metabolism, while CYP inducers may decrease exposure via enhanced clearance. Population-specific interaction risks may be more significant in patients with impaired hepatic function.

Азафен, chemically known as pipofezine, functions primarily in the central nervous system (CNS) as a reuptake inhibitor of the monoamine neurotransmitter serotonin (5-HT).

Its biological target is the serotonin transporter (SERT) protein located on the presynaptic neuronal membrane. Азафен binds to SERT, leading to the inhibition of the transporter's normal function of moving serotonin from the synaptic cleft back into the presynaptic neuron. This blockade of the reuptake mechanism results in a molecular pathway modification: an increase in the extracellular concentration of serotonin within the synaptic cleft.

The resulting elevated synaptic serotonin levels lead to a downstream cascade of sustained and increased activation of postsynaptic serotonin receptors. This prolonged receptor engagement is hypothesized to induce intracellular consequences involving alterations in gene expression and neuronal plasticity. At a system-level physiological consequence, the modification of serotonergic neurotransmission contributes to the modulation of neuronal signaling in brain regions associated with affective processing.

Official Administration and Dosing Guidelines

Азафен (Pipofezine) is an antidepressant for which dosing recommendations are standardized for clinical use. Standard guidelines define the required route of administration, the dosage ranges, and the administration frequency.

Administration Scope

Parameter	Instruction
Route of Administration	The medicine is for oral administration only, taken as a tablet.
Dosage Forms	Available as standard 25 mg tablets and potentially 150 mg modified-release tablets for maintenance.
Timing in Relation to Meals	No specific, mandatory instructions are provided in available documentation.
Age-Group Rules	Dosing regimens are established for adult patients.

Labeled Dosing and Schedule (Adults)

Treatment with Азафен is typically initiated with a low dose and gradually adjusted. The total daily dose must be administered in multiple, divided administrations throughout the day.

• Starting Dose: The initial total daily dose for adults is typically 25 mg to 50 mg, administered in two divided doses (morning and midday).
• Titration and Maintenance: Provided the starting dose is tolerated well, the dose is gradually increased to an optimal total daily range of 150 mg to 200 mg. This dose is usually split into three to four administrations throughout the day, with the last dose taken before sleep.
• Maximum Daily Dose: The maximum recommended total daily dose is between 400 mg and 500 mg (given in divided administrations).
• Duration: The full course of treatment may last up to one year, with a minimum duration of 1 to 1.5 months.

Upon achieving the desired response, the daily dose may be gradually reduced to a supportive maintenance level, typically between 25 mg and 75 mg per day.

Азафен: Research Evidence and Studies

---

Evidence for Use in Depressive Disorders

Research evaluating Азафен (Pipofezine) for use in depressive disorders is primarily based on randomized controlled trials (RCTs). These studies examined adult patients and typically compared the drug to a placebo (an inactive substance) or an active comparator medication over short observation intervals. Researchers monitored changes in symptom intensity using standardized depression rating scales. Findings described measured patterns in scores that were reported as varying among the study groups. Research highlights that these findings are derived from short-term study periods, and research does not determine whether an individual patient will respond similarly.

---

Comparing Азафен to Other Treatments

Some research has explored how the drug was evaluated against other active comparator medications by measuring changes in symptoms between the groups. Data describe patterns related to how these measurements varied between the study groups over the short duration of the research. In some cases, studies reported similar measurement patterns, while in other studies, the reported changes in measurements varied. Comparative evidence against many other types of medications is limited, and the existing research often involves different comparator agents.

---

Long-Term Studies and Evidence Gaps

The available clinical data are mainly focused on the acute treatment phase. The longest duration of patient follow-up in formal trials is generally limited, and long-term effects and the sustained status of patients are not fully established. This lack of data for periods beyond the acute phase contributes to the areas of uncertainty in the overall evidence landscape. Research is also limited for specific groups, such as younger individuals or pregnant-related populations. Studies monitoring use in older adults are generally older or more modest in size. Overall, the certainty of findings remains limited due to short follow-up durations, varied evidence quality, and a lack of comprehensive comparative data.

Key Studies & References

1. Comparative study of Pipofezine and selective serotonin reuptake inhibitors in patients with mild to moderate depression: A randomized controlled trial
2. Long-term monitoring and follow-up data of tricyclic antidepressant use: Implications for Pipofezine evidence

Common questions about Азафен (FAQ)

---

Q: Does Азафен interact with pain relievers, according to safety information?

Official information provides warnings about combining Азафен with other medications that act as Central Nervous System (CNS) Depressants. This restriction is due to the potential for the combined effect to increase sedation and impair coordination. The official warnings point to this potential interaction for individuals using pain relievers classified as CNS depressants, although specific pain relievers are not listed individually.

---

Q: Is there information on how to stop taking Азафен if treatment is complete?

According to the official administration guidelines, once the desired response is achieved, the daily dose may be gradually reduced to a supportive maintenance level. While the importance of a slow reduction is mentioned, detailed regulatory instructions on the process for complete discontinuation of the medication are not provided in the summary documents.

---

Q: Can Азафен be taken with common over-the-counter cold and flu medications?

Regulatory documents restrict co-administration with other Serotonergic Agents and CNS Depressants (medications that affect serotonin levels or slow down the nervous system). Many common over-the-counter cold and flu products contain ingredients that can interact with these systems. Therefore, understanding the ingredients of cold medications is important because of the potential for overlap with these restricted classes.

---

Q: How does the structure of Азафен differ from modern selective serotonin reuptake inhibitors (SSRIs)?

Азафен is classified structurally as belonging to the Tricyclic Antidepressant (TCA) group. This classification refers to the three-ring chemical structure of the compound. Modern selective serotonin reuptake inhibitors (SSRIs) have a distinct chemical structure and belong to a different pharmacological class.

---

Q: Is Азафен available in all countries, or is it specific to certain regions?

The primary regulatory documents providing the official prescribing instructions and dosage regimens are based on the Russian State Register of Medicines (RLS). This indicates that the information and availability are specific to the regions where this body provides drug authorization.

---

Q: Are there any known interactions between Азафен and contraceptive pills?

Official documents note that the metabolism of Азафен is handled by the Cytochrome P450 enzyme system, specifically CYP2D6. Medicines that are CYP2D6 inhibitors or inducers could potentially affect the plasma concentration of Азафен. However, the potential for interaction with specific types of hormonal contraceptive pills is not explicitly detailed in the regulatory summaries.

---

Q: Is there any specific monitoring suggested by doctors while a patient is on Азафен?

Official safety constraints emphasize that the medication has a potential for cardiotoxicity and note that Geriatric Patients may show increased sensitivity to side effects. The presence of these formal warnings may be a reason why clinical oversight is often required for these patient groups during treatment.

How to Store and Dispose of Азафен (Pipofezine)

Official regulatory labeling outlines specific storage and disposal requirements for Азафен tablets to ensure product stability and safety.

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is specified as 20 C to 25 C (68 F to 77 F). The tablets must be kept in a tight and light-resistant container to protect the active ingredient, Pipofezine, from moisture and light exposure. It is mandatory to keep Азафен out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

When disposing of expired or unused Азафен, follow official pharmaceutical waste guidelines. The preferred method is to utilize an authorized drug take-back program. If a take-back program is unavailable, tablets must be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a bag before being placed in the trash. Do not flush the medication down the toilet or pour it down a drain.